AREG and head and neck squamous cell carcinoma: To determine the contribution of AREG production to erlotinib sensitivity in MAPK1E322K mutated HNSCC models, we compared erlotinib responses in HSC-6 cells in the setting of AREG knockdown by shRNA compared with GFP-control.